Week in review: Teen antidepressant use during COVID, expert reaction to omalizumab data
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Image Credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, February 26 to Friday, March 1, 2024), and click on each link to read and watch anything you may have missed.
1.) Female teen antidepressant use rose, male teens saw a decline amid COVID-19
A new study found female teens and young adults were more likely to have an increased antidepressant dispensing rate during the pandemic than male peers.
Click here for more COVID-19 antidepressant data for adolescents and young adults.
2.) Experts share their thoughts on the omalizumab OUtMATCH phase 3 data
Study authors of a paper published in The New England Journal of Medicine highlighting omalizumab for multiple common food allergies provided their comments regarding positive phase 3 data.
Click here for full commentary from Robert Wood, MD, and Scott Sicherer, MD, FAAP.
3.) Can smartwatch technology identify arrhythmias in children with adult algorithms?
Scott Ceresnak, MD, explains smartwatch technology could be a great tool in detecting arrhythmias in children, however, given that algorithms in the technology were designed for adults, caution must be used as well.
Click here to watch the full interview.
4.) The role of the pediatrician in school-based mental health services
"Collaboration can help us make more accurate diagnoses, develop more effective multimodal treatment plans, and monitor progress in many areas," said James Wallace, MD.
Click here for the full interview.
5.) Long-term safety of epicutaneous immunotherapy with DBV712 for peanut allergy
A poster presentation at AAAAI from the phase 3 PEOPLE Study revealed DBV712 treatment in children with peanut allergy has a favorable safety and tolerability profile.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.
